Targeting of the JAK-STAT signalling pathway is of potential therapeutic value in a range of cutaneous T cell lymphomas, including MF/SS, primary cutaneous CD30-positive LPD, CD8+ AECTL, SCPTL and PCGDTCL. This evidence concerns the gene SOAT1 and primary cutaneous T-cell non-Hodgkin lymphoma.